Clinical and Translational Radiation Oncology · 2019 · 56 citations · 33 references
MedicineOncologyRadiation OncologyCardio-oncologyClinical Radiation OncologyThoracic OncologyCancer Survival AnalysisConcurrent ChemoradiationEsophageal CancerRadiation TherapyRadiation ToxicityRadiobiological ConsiderationsCardiac Radiation DosimetryConcurrent Chemoradiotherapy ToxicityIntensity-modulated Radiation Therapy DosimetryIntensity-modulated Radiation Therapy EffectsKaplan-meier Confidence IntervalsMean Heart DosePostoperative Cardiac ComplicationsRadiation-induced Cardiac Injury
Purpose: To analyze associations between heart and lung dose and overall survival (OS) in patients with esophageal cancer who received concurrent chemo-radiotherapy (CCRT) with or without surgery. Patients and methods: Patients received intensity-modulated radiation therapy (median dose 50.4 Gy) from 2004 through 2016. Cutoff points for continuous variables were calculated using the method of Contal and O'Quigley. Kaplan-Meier method with log-rank tests was used to calculate survival. OS was analyzed with both univariate and multivariable Cox models. Results: In all, 560 patients were analyzed; median follow-up time was 29.3 months, and 5-year OS rate was 41.7%. Heart V30 >45% and mean lung dose (MLD) >10 Gy were found to be independently associated with worse survival after adjustment for other clinical and dosimetric factors (P < 0.05). Heart and lung doses were also found to be risk factors for radiation-induced cardiac and pulmonary complications (P < 0.05): 8.5% of patients with heart V30 45% had cardiac complications vs. 15% for V30 >45% (P = 0.046); 18.8% of patients with MLD 10 Gy had pulmonary complications vs. 27% for MLD >10 Gy (P = 0.020). Having cardiac complications was associated with worse survival (5-year OS rates 27.6% with vs. 43.2% without, P = 0.012), and having pulmonary complications was associated with worse survival as well (5-year OS rates 23.1% with vs. 47.4% without, P < 0.001). Conclusion: Both heart and lung doses independently predicted worse OS in patients with esophageal cancer, even after adjustment for other clinical and dosimetric factors, and were also risk factors for radiation-induced complications. Both irradiated heart and lung doses should be minimized as a whole.
33
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Sarah C. Darby, Marianne Ewertz, Paul McGale et al. · New England Journal of Medicine · 2013 · 4K citations · Full text
Medicine, Cardiology, Oncology +17
Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.6K citations
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text
Chemoradiotherapy of Locally Advanced Esophageal Cancer
Jay S. Cooper, Matthew Guo, Arnold Herskovic et al. · JAMA · 1999 · 2K citations